iBio's IBIO-610 Shows Near-Total Activin E Inhibition in Obese Primates — iBio, Inc.

Event summary

Single dose of IBIO-610 achieved 98% inhibition of active Activin E through eight weeks in obese non-human primates.
When combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone.
Full dataset to be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting on October 1, 2026.

The big picture

iBio's data suggests a potential breakthrough in long-acting antibody therapeutics for obesity, addressing both fat loss and lean mass preservation. The results position Activin E blockade as a key differentiator in a market increasingly focused on durable, body-composition-focused treatments. The upcoming presentation at EASD will be critical for validating these findings with the scientific community.

What we're watching

Clinical Translation: Whether the near-complete Activin E inhibition observed in non-human primates will translate to similar efficacy and safety in human clinical trials.
Market Differentiation: How iBio positions IBIO-610 as a complementary therapy to existing GLP-1-based treatments, given the competitive obesity market landscape.
Regulatory Pathway: The pace at which iBio advances IBIO-610 through regulatory approvals, particularly in light of the evolving standards for obesity therapies.